Trial Profile
Phase I-II study of F14512 in combination with cytarabine in patients 60 years old and older with acute myeloid leukemia.
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 10 Nov 2018
Price :
$35
*
At a glance
- Drugs F 14512 (Primary) ; Cytarabine
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pierre Fabre
- 15 Feb 2018 Status changed from recruiting to discontinued.
- 21 Oct 2014 New trial record